ClinicalTrials.gg
CompletedNCT03568500Updated Jul 16, 2020Results posted

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

A Phase 4 interventional study of Digital Medicine System and Aripiprazole in Schizophrenia, Schizoaffective Disorder and First Episode Psychosis, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
96th of 125
44 · median 130
Started
2018
with 3 others
Phase 4
56 of 126
2 open now
Registered
111th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 96th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2018, is one of 56 in phase 4, and was the 111th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use. The DMS is being developed as a healthcare management tool to precisely measure medication adherence and to potentially enhance adherence.

Read the detailed description

The advancements in the treatment of mental health patients with DMS will enable healthcare professionals to assess suboptimal adherence and make more informed treatment decisions. In addition to these improvements, it will also provide a platform for engagement between participants, healthcare professionals, and caregivers/support persons.

Participants who entered the trial were treated with one of the oral atypical antipsychotics defined in the trial (aripiprazole, olanzapine, quetiapine, or risperidone [though no participant took risperidone in this trial]). The treatment medication decision was determined by the healthcare professionals.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • First Episode Psychosis

Keywords

  • Digital Medicine System
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant was prescribed aripiprazole, olanzapine, quetiapine, or risperidone.
  • Participant possessed a smartphone, or a smartphone provided by the Sponsor, and was willing to download and interact with the DMS app.
  • Skin on the anterior chest just above the lower edge of the rib cage was free of any dermatological problems (for example, open wounds, warts, rashes, atopic dermatitis).

Exclusion criteria

Exclusion Criteria:

  • Participant with a known allergy to adhesive tape or any pertinent components of the patch or CoE product.
  • Prisoners could not be enrolled into this trial.
  • Participant who was hospitalized due to mental or physical illness (inpatient) at the time of screening/baseline.
  • Any participant who, through religious or lifestyle choices, would not take gelatin capsules.
  • Female of who was breast-feeding and/or who had a positive pregnancy test result prior to receiving trial enrollment, or who planned to become pregnancy during the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.

    Device: Digital Medicine System · Drug: Aripiprazole

  • Experimental
    Olanzapine

    Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.

    Device: Digital Medicine System · Drug: Olanzapine

  • Experimental
    Quetiapine

    Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.

    Device: Digital Medicine System · Drug: Quetiapine

  • Experimental
    Risperidone

    Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.

    Device: Digital Medicine System · Drug: Risperidone

Interventions

  • DeviceDigital Medicine System

    DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).

  • Dosage determined by the healthcare professionals.

  • Dosage determined by the healthcare professionals.

  • Dosage determined by the healthcare professionals.

  • Dosage determined by the healthcare professionals.

06

What researchers measure

Primary outcomes

  1. Percentage Of Days With Good Patch Coverage

    The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \[MIT\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Participant Adherence

    The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.

    Time frame: Up to 8 weeks

07

Results

Posted Jul 16, 2020

Participant flow

The trial enrolled participants with a confirmed clinical diagnosis of schizophrenia, schizoaffective disorder, or first episode psychosis.

Participant flow — Overall Study
MilestoneAripiprazoleOlanzapineQuetiapine
Started18206
Received at least 1 dose of study drug18196
Completed8142
Not completed1064
Withdrew: Lost to follow-up112
Withdrew: Adverse event112
Withdrew: Physician decision100
Withdrew: Withdrawal by subject420
Withdrew: Technical problems210
Withdrew: Participant noncompliance110

Outcome measures

PrimaryPercentage Of Days With Good Patch Coverage

The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (miniature ingestible event marker in tablet \[MIT\]). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Good patch coverage for a specific day was defined as having either at least 80% patch data available (80% of the day the patch was worn and data was collected as noted via the accelerometer channel) or the MIT was detected within the 24-hour period, for each day while the participant was in the trial. The percentage of days was calculated as the number of days with good patch coverage divided by the total number of trial days for each participant. Descriptive statistics were performed for this outcome measure.

Time frame:
Up to 8 weeks
Reported as:
Mean · percentage of days
Percentage Of Days With Good Patch Coverage
percentage of daysSchizophreniaSchizoaffective DisorderFirst Episode PsychosisTotal
Percentage Of Days With Good Patch Coverage64.34 ± 20.2462.99 ± 37.6862.51 ± 27.5363.37 ± 26.60
SecondaryParticipant Adherence

The DMS includes a drug-device combination of a CoE product, a wearable sensor patch, and application software (smartphone) to record activity and rest and mark events through the act of ingestion. The CoE product consists of an approved antipsychotic medication enclosed with an Ingestible Sensor Pill (MIT). The sensor patch detects and records each MIT ingestion, as well as other physiologic and behavioral data. Participant adherence was measured as the detected MITs over the expected MITs ingested during the trial days with good patch coverage. The more the participant successfully engaged in a number of processes across the 8-week trial, the greater the measured adherence. Descriptive statistics were performed for this outcome measure.

Time frame:
Up to 8 weeks
Reported as:
Mean · percentage of MITs
Participant Adherence
percentage of MITsSchizophreniaSchizoaffective DisorderFirst Episode PsychosisTotal
Participant Adherence88.94 ± 8.0672.29 ± 25.6591.04 ± 7.3786.57 ± 14.47

Adverse events

Collected over Baseline to Week 24 (+ 7 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole0/18 (0%)0/18 (0%)4/18 (22.2%)
Olanzapine0/19 (0%)0/19 (0%)2/19 (10.5%)
Quetiapine0/6 (0%)0/6 (0%)3/6 (50%)
Total0/43 (0%)0/43 (0%)9/43 (20.9%)
Most frequent other events
Most frequent other events
EventAripiprazoleOlanzapineQuetiapineTotal
Medical device site irritationGeneral disorders4/182/193/69/43

Baseline characteristics

Enrolled Population: All participants who signed an informed consent form and entered the trial (and only participants who met all of the inclusion criteria and none of the exclusion criteria).

Age, Continuous
Age, Continuous(Years)AripiprazoleOlanzapineQuetiapineTotal
Mean31.6 ± 9.638.0 ± 11.430.8 ± 8.834.4 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)AripiprazoleOlanzapineQuetiapineTotal
Female84315
Male1016329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AripiprazoleOlanzapineQuetiapineTotal
Hispanic or Latino0000
Not Hispanic or Latino1718540
Unknown or Not Reported1214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AripiprazoleOlanzapineQuetiapineTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American4408
White1415635
More than one race0000
Unknown or Not Reported0101
Disease Diagnosis
Disease Diagnosis(Participants)AripiprazoleOlanzapineQuetiapineTotal
Schizophrenia513018
Schizoaffective Disorder44210
First Episode Psychosis93416
08

Study locations

5 sites
  • Clinical Trial Site
    Chertsey, United Kingdom
  • Clinical Trial Site
    London, United Kingdom
  • Clinical Trial Site
    Newcastle Upon Tyne, United Kingdom
  • Clinical Trial Site
    Oxford, United Kingdom
  • Clinical Trial Site
    Southampton, United Kingdom
09

References and documents

Publications

  • Fowler JC, Cope N, Knights J, Phiri P, Makin A, Peters-Strickland T, Rathod S. Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis. BMJ Open. 2019 Jun 27;9(6):e025952. doi: 10.1136/bmjopen-2018-025952. PubMed 31253613 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in May 2019, 12 months.

Results were first posted in Jul 2020, 1 year 1 month after primary completion.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jun 26, 2018
StartActual
May 21, 2018
Primary completionActual
May 21, 2019
CompletionActual
Sep 6, 2019
Results first posted
Jul 16, 2020
Last update
Jul 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03568500
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
May 21, 2018
Primary completion
May 21, 2019
Completion
Sep 6, 2019
Results posted
Jul 16, 2020
Last update
Jul 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Olanzapine · Quetiapine · Risperidone

Start the discussion